Loading briefing details...
Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Health,Industry,Science & Environment
September 15, 2026
Creative Biolabs has introduced a integrated suite of services designed to assist researchers in evaluating complex biotherapeutics. The new offerings focus on immune-response characterization and the adoption of advanced experimental models.
The company is now providing specialized assays to measure anticomplementary activity and analyze macrophage polarization. These tools are intended to help scientists better understand how therapeutic candidates interact with the human immune system during early-stage development.
In addition to immunology services, the firm has expanded its microfluidic capabilities. By offering custom chip development, the company aims to help laboratories improve experimental precision while reducing sample volume requirements.
As the biopharmaceutical industry shifts toward more diverse modalities like gene therapies and complex nanoparticles, traditional static testing methods are becoming insufficient. Researchers face increasing pressure to generate high-quality preclinical data that accurately predicts human immune responses.
The integration of microfluidic platforms into these workflows represents a broader industry trend toward miniaturization and high-throughput screening. By combining precise cellular environment control with specific immunological assays, labs can now better navigate the technical hurdles associated with modern drug discovery and candidate validation.